@Article{, title={Lenalidomide‑related malar rash‑like lesion in patient with 5q‑syndrome}, author={Gokhan Sargin and Irfan Yavasoglu}, journal={Iraq Joural of Hematology المجلة العراقية لامراض الدم}, volume={8}, number={1}, pages={45-47}, year={2019}, abstract={It has become important to be careful in terms of side effects with the increased lenalidomide use.The most commonly reported adverse events with the use of lenalidomide were hematologic toxicitiesand less frequently peripheral edema, infections, gastrointestinal disorders, fatigue, and musclecramps. In particular, the nonserious rash is the most common cause of permanent discontinuationof lenalidomide. Although morbilliform, urticarial, or acneiform rashes have been observed withlenalidomide, malar rash‑like lesions have not been described previously. Our aim is to present here71‑year‑old female myelodysplastic syndrome patient with deletion of 5q abnormality who should bediscontinued lenalidomide due to recurrent skin reaction like a malar rash.

} }